Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Sintilimab + Lenvatinib for Recurrent or Metastatic Meningioma
ChiCTR2300078896Phase 2Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and lenvatinib in meningioma, sponsored by General Hospital of the Northern Theater Command. Primary endpoint: 6-month progression-free survival rate. Started Dec 2023; status: recruiting.
02
Drugs
sintilimablenvatinib
03
Conditions
meningioma
Beyond the preview
Go deeper on ChiCTR2300078896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078896.